Presidio, BioCryst call off $101 million merger

Presidio Pharmaceuticals is leaving BioCryst Pharmaceuticals ($BCRX) at the altar. The companies announced today that their $101 million marriage is off. What broke up the two, whose hepatitis C pipelines seemed so compatible? Ever since the engagement was announced in October, BioCryst has had one pipeline disaster after another. It killed plans for an early-stage trial of its experimental NS5B inhibitor BCX5191 over toxicity concerns. Its late-stage study of its flu drug peramivir crashed and then BioCryst announced that the FDA slapped a clinical hold on development of BCX41 for hereditary angioedema.
Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.